🇺🇸

US SEC Filing Intelligence

· daily

New Drug Approvals (Original) — March 13, 2026

FDA approved 7 original ANDA generic drugs on March 9-10, 2026, all under standard review with no special designations, therapeutic areas, or indications specified. These routine approvals enable market entry for smaller sponsors but carry neutral investment signals due to commoditization and lack of premium positioning. Cross-cutting pattern: uniform low-impact generics signal steady but non-disruptive pipeline activity, warranting monitoring for sponsor portfolio accumulation amid pricing risks.

7 total filings
· daily

DHS Homeland Security Contracts — March 13, 2026

DHS awarded $823M across 4 contracts in border wall construction, immigration detention/security, and disaster support, signaling sustained federal spending priorities through 2028. All bullish signals highlight revenue visibility from fully or partially obligated values, with $560M (68%) concentrated in Texas border infrastructure. Investors should prioritize public parents Fluor Corp and CoreCivic for near-term cash flow from high outlays and options upside totaling ~$360M unexercised.

4 total filings
· daily

VA Healthcare & Services Contracts — March 13, 2026

VA Healthcare awarded $136.9M in obligations across two contracts (IT services and architectural design), signaling robust demand for digital and physical infrastructure upgrades with potential upside to $273.4M via options. General Dynamics IT benefits from 37% outlay ($29.5M) indicating steady cash flow to 2029, while Hellmuth, Obata & Kassabaum gains 19-year visibility to 2028 despite slow 2.6% outlay start. Firm-fixed-price terms introduce margin risks, but full/open competition awards to non-SB firms underscore sector stability for institutional exposure.

2 total filings
· daily

HHS & Healthcare Contracts Intelligence — March 13, 2026

HHS obligated $796M across two health R&D contracts, led by a dominant $724M BARDA biotech award to nonprofit Advanced Technology International, providing 7+ year spending visibility but no equity upside. Bullish signal from Technical Resources International's $73M (potential $337M) NIAID clinical research contract, with 50% of obligated funds already outlayed since 2024. Low average outlays (~10% of obligated value) highlight execution risks, while long-term horizons to 2030-2031 underscore sustained health preparedness trends warranting sector monitoring.

2 total filings
· daily

Federal Construction & Infrastructure Contracts — March 13, 2026

Two firm-fixed-price federal contracts totaling $900M in NAICS 236220 (commercial/institutional building) provide committed revenues to non-small business constructors through 2028, signaling sustained U.S. government demand for border security and diplomatic infrastructure. Barnard Spencer JV's $561M Texas border wall and Caddell Construction's $339M Turkmenistan embassy represent full options exercised via open competition, with zero outlays to date implying phased funding. Investors gain clear bullish exposure to large-scale execution but must flag cost overrun and delay risks.

2 total filings
· daily

Federal Professional Services Contracts — March 13, 2026

Five bullish federal professional services contracts total $757M in obligations, with GSA dominating (4/5 awards) and SAIC capturing 58% ($447M across two deals), signaling entrenched positioning for large contractors in engineering and admin services. Unexercised options offer $309M+ upside potential across the portfolio, while long-duration awards (e.g., Ameresco to 2047) highlight stable revenue visibility amid disaster response and energy retrofit priorities. Risks center on execution in extended periods and high subcontract pass-throughs (up to $457M in one deal), but early outlays in recent awards like Fluor's $77M indicate funding momentum.

5 total filings
· daily

Federal IT & Cybersecurity Contracts — March 13, 2026

Four bullish federal IT/cybersecurity contracts total $318.98M obligated (avg 70% outlayed), signaling robust execution and demand from HHS ($172.5M), VA ($78.7M), and DOJ ($67.8M). Firm fixed price delivery orders feature $521.47M potential via options, extending to 2029 and adding ~64% upside. Mix of large (GD, Iron Vine) and small businesses (SparkSoft, Seneca) winning full/open comp highlights sector accessibility and multi-year revenue visibility.

4 total filings
· daily

New Federal Contractors — March 13, 2026

This batch of 21 new federal contracts totals $3.6B in obligations, with 17 bullish signals dominated by long-term health R&D, border security construction, and IT/cybersecurity services, providing revenue visibility through 2047. Public companies like SAIC ($446.8M across two awards), Fluor, General Dynamics IT, Northrop Grumman, Ameresco, and CoreCivic capture ~15% of value with options upside averaging 40% above obligations. Firm fixed price structures prevail (70% of contracts), flagging execution risks amid low average outlays (22% of obligated).

21 total filings
· daily

Significant Contract Modifications ($10M+) — March 13, 2026

Federal contract modifications totaling $3.6B signal robust demand in border infrastructure ($618M), health R&D/services ($1.1B+), and IT/cybersecurity ($500M+), with 17 bullish signals dominated by long-term awards to public firms like SAIC ($447M across 2), Fluor, and CoreCivic. Revenue visibility extends to 2047 for energy retrofits and 2031 for stewardship/embassies, though firm-fixed-price prevalence (14/21) heightens execution risks amid low average outlays (26% of obligations). Investors should prioritize defense/IT primes and construction for near-term cash flows, monitoring option exercises adding $1.5B+ potential value.

21 total filings
· daily

Contract Deobligations Alert — March 13, 2026

This $3.6B contract deobligations alert reveals 17 bullish signals dominated by long-term federal obligations in health services, border infrastructure, and IT/cybersecurity, with total upside from unexercised options exceeding $2B across records. Publicly traded firms like SAIC (2 awards, $446.8M obligated), Fluor ($134.5M), and Northrop Grumman ($64M) show strongest direct equity exposure amid low outlays signaling potential funding restarts. Neutral signals cluster in nonprofits/low-outlay health R&D, limiting investable upside; prioritize border construction and HHS IT for near-term revenue ramps.

21 total filings
· daily

Contract Option Exercises — March 13, 2026

21 contract option exercises totaling $3.6B signal robust federal spending commitments through 2047, predominantly bullish (17/21) across HHS (health IT/cyber), DHS (border/detention/disaster), and GSA/VA (engineering/energy). Publicly traded beneficiaries like SAIC ($446.8M aggregate), Fluor, General Dynamics IT, Northrop Grumman, Ameresco, and CoreCivic gain multi-year revenue visibility amid FFP/T&M structures. Neutral signals limited to nonprofits/low outlays; prioritize monitoring option exercises ($1B+ potential) and execution on long-duration projects.

21 total filings
· daily

All HHS Contracts — March 13, 2026

HHS awarded $1.26B across 7 contracts, with 57% bullish signals concentrated in CMS-driven cybersecurity, IT development, and Medicare communications, signaling robust near-term revenue for service providers. Recent awards (2024) show rapid outlays averaging 60% of obligations, indicating execution momentum and $800M+ in unexercised options for upside. Neutral signals from nonprofits and matured contracts limit broad equity plays, prioritizing small/disadvantaged businesses in health IT and R&D.

7 total filings
· daily

Mega Contracts Monitor ($100M+) — March 13, 2026

This week's $2.85B mega contracts show 80% bullish signals, dominated by long-term federal awards in construction ($900M+ combined), health services/R&D ($1B+), and engineering/cyber ($900M+), providing multi-year revenue visibility to 2047. Public companies like SAIC, Fluor, Caddell, and Ameresco capture significant GSA/DHS/State wins with options upside averaging 30-50% above obligations. Risks center on firm-fixed-price overruns and low initial outlays (avg. 20-30% drawn), but opportunities in follow-ons and extensions outweigh for construction/energy sectors.

10 total filings
· daily

High-Value Federal Grants ($5M+) — March 13, 2026

Federal high-value contracts totaling $3.6B show 17 bullish signals dominated by long-term HHS health R&D/services ($1.2B+), DHS border/detention/disaster ($823M), and GSA engineering/IT ($886M), signaling sustained gov spending momentum into 2030+. Public companies like SAIC (2 awards, $447M), Fluor ($134M), and CoreCivic ($57M) offer direct equity upside via options/exercises averaging 30-100% above obligations. Risks center on firm fixed price structures (12/21 contracts) and low outlays in 40% of awards, but rapid disbursements in recent IT/health wins ($36-90M outlayed) indicate execution strength.

21 total filings
· daily

General Federal Contracts — March 13, 2026

21 federal contracts totaling $3.6B awarded or active, with 17 bullish signals dominated by health services (HHS/CMS/VA ~$1.5B), border/detention security (DHS/ICE ~$823M), and IT/engineering (GSA ~$934M), signaling sustained federal spending in preparedness, infrastructure, and cyber/IT amid long-term performance periods to 2047. Public companies like SAIC ($447M across 2), Fluor, Northrop Grumman, and CoreCivic gain committed revenue with options upside >$1B potential. Neutral signals limited to nonprofits/low-outlay deals; risks center on firm-fixed-price overruns and funding delays, but high outlays in recent awards ($222M+ in several) indicate execution momentum.

21 total filings
· daily

S&P 500 Consumer Staples Sector SEC Filings — March 13, 2026

Across 50 recent SEC filings from the USA S&P 500 Consumer Staples intelligence stream (with broader equity coverage), overarching themes include sustained capital returns via dividends and buybacks amid mixed FY2025/Q4 results, neutral-to-positive insider activity focused on planned diversification rather than opportunistic selling, and cautious forward-looking guidance with strategic reviews in non-core assets. Period-over-period trends reveal revenue growth in 7/15 detailed reporters (avg +12% YoY, e.g., monday.com +27%, CCEP +FX-neutral), but margin compression in 6/15 (avg -100bps, e.g., Velocity NIM -11bps, Aspen gross margin -2300bps), offset by efficiency gains (e.g., Fidelity D&D efficiency ratio -590bps to 60.3%). Critical developments feature CCEP's strong €20.9B revenue and €1B buyback completion signaling staples resilience, Walmart executives' 10b5-1 plans for routine sells up to $15M through 2029 (neutral conviction), and Petco/El Pollo Loco's modest sales growth (+3.6%/-2.5%) with profitability improvements. Portfolio-level patterns show 9/50 filings with dividends/buybacks (e.g., GIII $0.10, Ford 31.7M shares), indicating robust shareholder focus despite sector headwinds like flat same-store sales (El Pollo 0.1%). M&A/strategic processes (e.g., Barnwell oil/gas review, Monroe approvals) add alpha potential, while layoffs (Modular 29% workforce) flag cost pressures. Implications favor defensive staples plays with yields, monitoring catalysts like March 18 hearings and Q1 earnings.

26 high priority 24 medium 50 total filings
· daily

S&P 500 Industrials Sector SEC Filings — March 13, 2026

Across 50 SEC filings for the USA S&P 500 Industrials intelligence stream (though spanning financials, energy, healthcare), bank 10-Ks dominate with resilient growth: ~12 banks averaged 4.5% YoY asset growth, 12% YoY NII increase, and 20bps NIM expansion (e.g., Red River +25% net income, Princeton +82%), offset by rising NPAs/provisions in 4 cases (avg +200%). Industrials shine with Venture Global's landmark $20.7B CP2 LNG financing (Phase 2 FID $8.6B, no equity needed, targeting 100+ MTPA capacity), Ducommun's record $824.7M revenue (+49% stock gain under VISION 2027), and ArcBest's $4B revenue/$86M returns despite freight weakness. Capital allocation trends positive: 5 dividends (GIII $0.10, Designer $0.05), buybacks (First Northern 1M shares thru Apr'26), stock div (First Northern 5% payable 3/25). Forward-looking catalysts include Better Home's Q1'26 loan vol guide $1.4-1.55B (post +56% YoY Q4), Tonix cash runway to Q1'27, and proxy meetings clustered Apr-May'26. Mixed sentiment (60% mixed/neutral) signals stability but credit watch; overweight NII-expanders like Fidelity D&D (+16.7% NII), avoid NPA outliers like Isabella (+553%). Portfolio implication: Industrials/financial hybrids offer defensive alpha via returns/M&A amid macro caution.

34 high priority 16 medium 50 total filings
· daily

S&P 500 Energy Sector SEC Filings — March 13, 2026

Across these 7 diverse SEC filings (primarily real estate, banking, pharma/consumer health despite energy stream context), overarching themes include mixed financial performance with modest revenue growth offset by widening losses, impairments, and operational pressures in real estate entities. Period-over-period trends reveal revenue increases (BRT +1.5% YoY to $97M, Copper lease income +2% YoY to $96M, John Marshall NII +18.6% YoY) but declining profitability (BRT FY net loss to $(11.9M) from $(9.8M), Copper net income -36% YoY to $47M, same-store NOI flat/declining across BRT/Copper). Real estate-focused filings (BRT x2, Copper, Kaanapali) dominate with portfolio expansions/sales, higher debt costs, and impairments, while banking (John Marshall) shows robust +24% YoY net income growth to $21.2M and Haleon delivers clean audits. Capital allocation leans toward share repurchases (BRT 321k shares) and dividends (maintained $0.25 Q at BRT, $0.30 at John Marshall), but no insider trading patterns noted. Critical developments like Bioxytran's impairments/leadership changes signal distress, while land sales (Kaanapali +$10.3M gain) and bank asset growth (+4.4% to $2.33B) offer pockets of strength. Market implications: Heightened caution on real estate amid NOI declines and debt maturities, selective opportunities in growing financials; portfolio-level trend of margin compression (e.g., Copper NOI -7%, BRT AFFO flat) suggests broader sector vulnerability.

6 high priority 1 medium 7 total filings
· daily

S&P 500 Financials Sector SEC Filings — March 13, 2026

Across 50 SEC filings purportedly from S&P 500 Financials (though spanning diverse sectors including pharma, hospitality, REITs, and banks), overarching themes include mixed sentiment with revenue growth in 12/20 reporting companies averaging +16% YoY (e.g., ONE Group +19.7%, Emerald +16.2%, Jefferson Capital +41.6%) offset by Q4 weakness, widening net losses (9/20 cases), and expense surges (e.g., Tonix SG&A +119%). True financials like Red River Bancshares (+25% net income, NIM +14bps to 3.38%), First Northern (+4.8% NII, NIM +17bps), Republic Bancorp (NPS +12% to 73.4), and Jefferson Capital (+45.8% net income) show resilience amid deposit declines elsewhere. Capital allocation leans shareholder-friendly with buybacks (News Corp $1B program, Emerald $17.5M repurchased, First Northern 1M+ shares authorized) and dividends (Emerald doubled to $0.06/share, BRT $0.25 Q). Insider activity limited to routine Walmart 10b5-1 plans (e.g., McMillon 155k shares). Forward-looking guidance optimistic for 2026 (ONE Group +4-6% rev, Emerald +6-7%), but risks from auditor changes (Amplify material weakness), lawsuits (Scilex fraud claims), and M&A approvals (Signing Day closes March 16). Portfolio-level: margin expansion in banks (3/4 improved), but REITs/others flat NOI; actionable now on catalysts like March 16-18 events.

30 high priority 20 medium 50 total filings
· daily

US Material Events SEC 8-K Filings — March 13, 2026

The 50 8-K filings from March 13, 2026, reveal a surge in financing activities (12+ cases), including credit expansions, note issuances, and debt-for-equity swaps, signaling robust liquidity amid stable economic conditions; energy firms dominate positive developments with accretive acquisitions and $20.7B+ project financings. Executive transitions affect 15+ companies (resignations/appointments), mostly neutral/mixed but clustered in tech/healthcare, potentially signaling churn without major disagreements. Capital allocation trends favor shareholders via $10M repurchases (HealthStream), buyback permissions ($50M AMC), and hedging (Vitesse 67% 2026 oil hedged at $64-67/Bbl), contrasting dilutive raises (Olenox Series C, Functional Brands exchanges). M&A/asset sales (7 cases) show mixed pro forma impacts, e.g., Kaanapali $10.3M gain but sales declines YoY. No widespread margin compression; instead, operational enhancements (Battalion 30 drilling locations added) and forward contracts (ETHZilla 12-13% yields). Highest materiality events (10/10: IF Bancorp merger delist, Venture Global FID) imply sector rotation to energy/LNG; watch fintech tokenization and REIT dispositions for alpha.

50 high priority 50 total filings